This resolution gives the WHO the go-ahead to expand its work on a range of issues, including the effects of international trade agreements, that affect access, quality, and rational use of drugs. Brundtland said the WHO is working with the WTO to ensure pharmaceutical innovation coupled with reasonable prices of pharmaceuticals. She strongly endorsed compulsory licensing and parallel imports. Some participants in the meeting criticized the lack of specificity in his remarks. Others, especially those from African countries, said they look to the WHO for leadership and expressed hope that the organization would take a strong position on these issues.
New drugs are already very expensive and are likely to become more so.
People in the United States who lack comprehensive health insurance are especially at risk of not having access to new innovative drugs. There seemed to be a consensus among participants at the meeting that the WTO is here to stay, but that there is a need for more health and public health concerns.